Insilico Medicine launched what it says is the first Drug Discovery and Development Benchmark as a Service for frontier AI models, designed to test whether systems can make meaningful scientific decisions rather than overfitting to training data recall. The benchmark is positioned as a response to weaknesses in existing evaluations that may not reflect real-world drug discovery workflows.